1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer

被引：0
|
作者：
Markus Mayrhofer
Hanna Göransson Kultima
Helgi Birgisson
Magnus Sundström
Lucy Mathot
Karolina Edlund
Björn Viklund
Tobias Sjöblom
Johan Botling
Patrick Micke
Lars Påhlman
Bengt Glimelius
Anders Isaksson
机构：
[1] Uppsala University,Science for Life Laboratory, Department of Medical Sciences
[2] Uppsala University,Department of Surgical Sciences
[3] Uppsala University,Science for Life Laboratory, Department of Immunology Genetics and Pathology
[4] Uppsala University,Department of Radiology, Oncology and Radiation Science
[5] Leibniz Research Centre for Working Environment and Human Factors,undefined
来源：
BMC Cancer | / 14卷
关键词：
Colon cancer; Prognostic marker; Allele-specific copy number analysis; Genome duplication; 1p36; Metastasis; Tumour dissemination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Topoisomerase IIβ binding protein 1 serves as a novel prognostic biomarker for stage II-III colorectal cancer patients
    Wang, Ying
    Yan, Xuebing
    Qu, Xiao
    Mao, Jingxian
    Wang, Jiaxin
    Yang, Mengxue
    Tao, Min
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 241
  • [42] Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): A pilot within the PROTECT study
    Derksen, J. W. G.
    Koopman, M.
    Huinink, D. ten Bokkel
    Sommeijer, D. W.
    Dorresteijn, B.
    Jourdan, M.
    May, A. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 735 - 735
  • [43] Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications
    Craig, Stephanie G.
    Mende, Svenja
    Humphries, Matthew P.
    Bingham, Victoria
    Viratham Pulsawatdi, Amelie
    Loughrey, Maurice B.
    Coleman, Helen G.
    McQuaid, Stephen
    Wilson, Richard H.
    Van Schaeybroeck, Sandra
    James, Jacqueline A.
    Salto-Tellez, Manuel
    MOLECULAR ONCOLOGY, 2021, 15 (12) : 3317 - 3328
  • [44] Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer
    Mezheyeuski, Artur
    Hrynchyk, Ina
    Karlberg, Mia
    Portyanko, Anna
    Egevad, Lars
    Ragnhammar, Peter
    Edler, David
    Glimelius, Bengt
    Ostman, Arne
    SCIENTIFIC REPORTS, 2016, 6
  • [45] FOLFOX4/XELOX in stage II-III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
    Zaniboni, A.
    Lonardi, S.
    Labianca, R.
    Di Bartolomeo, M.
    Rosati, G.
    Ronzoni, M.
    Pella, N.
    Banzi, M.
    Zampino, M. G.
    Pasini, F.
    Marchetti, P.
    Rimassa, L.
    Maiello, E.
    Bidoli, P.
    Cinieri, S.
    Barni, S.
    Ciuffreda, L.
    Beretta, G.
    Frontini, L.
    Rulli, E.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] FOLFOX4/XELOX in stage II-III colon cancer: Early survival data of the Italian three or six colon adjuvant (TOSCA) trial
    Roberto, Labianca
    Claudia, Mucciarini
    Paolo, Bidoli
    Domenico, Corsi
    Vincenzo, Montesarchio
    Maria, Bochicchio Anna
    Vincenzo, Iaffaioli
    Andrea, Ciarlo
    Sabino, De Placido
    Domenico, Amoroso
    Enrico, Cortesi
    Bruno, Daniele
    Dino, Amadori
    Daniele, Turci
    Silvia, Pelliccioni
    Saverio, Cinieri
    Alberto, Ravaioli
    Elena, Piazza
    Eliana, Rulli
    Alberto, Sobrero
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] FOLFOX4/XELOX in stage II-III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
    Labianca, R.
    Lonardi, S.
    Rosati, G.
    Di Bartolomeo, M.
    Ronzoni, M.
    Pella, N.
    Scartozzi, M.
    Banzi, M.
    Zampino, M. G.
    Pasini, F.
    Marchetti, P.
    Cantore, M.
    Zaniboni, A.
    Rimassa, L.
    Ciuffreda, L.
    Barni, S.
    Zagonel, V.
    Maiello, E.
    Rulli, E.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Microsatellite instability status as a predictive marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer.
    Zaanan, A.
    Flejou, J.
    Emile, J.
    Validire, P.
    Louvet, C.
    Rougier, P.
    De Gramont, A.
    Praz, F.
    Taieb, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [49] FOLFOX4/XELOX in stage II-III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.
    Sobrero, Alberto F.
    Lonardi, Sara
    Rosati, Gerardo
    Di Bartolomeo, Maria
    Ronzoni, Monica
    Pella, Nicoletta
    Scartozzi, Mario
    Banzi, Maria
    Zampino, M. Giulia
    Pasini, Felice
    Marchetti, Paolo
    Cantore, Maurizio
    Zaniboni, Alberto
    Rimassa, Lorenza
    Ciuffreda, Libero
    Ferrari, Daris
    Zagonel, Vittorina
    Maiello, Evaristo
    Rulli, Eliana
    Labianca, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX
    Ramaswamy, Anant
    Kothari, Rushabh
    Desouza, Ashwin
    Gupta, Tarachand
    Kapoor, Akhil
    Bairwa, Sandeep
    Kumar, Amit
    Ventrapati, Pradeep
    Ramadwar, Mukta
    Mandavkar, Sarika
    Chavan, Nita
    Saklani, Avanish
    Ostwal, Vikas
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (03) : 160 - +
12345